---
figid: PMC7934064__10.1177_1179554921996288-fig2
figtitle: Mechanisms involved in DDR and checkpoint immunotherapies
organisms:
- Homo sapiens
- Mus musculus
- Human gammaherpesvirus 4
organisms_ner:
- Mus musculus
- Homo sapiens
- Danio rerio
- Arabidopsis thaliana
pmcid: PMC7934064
filename: 10.1177_1179554921996288-fig2.jpg
figlink: pmc/articles/PMC7934064/figure/fig2-1179554921996288/
number: F2
caption: The mechanisms involved in DDR and checkpoint immunotherapies. (A) PARPi
  promote antigen presentation by ICD owing to the failure of DNA repair; (B) PARPi
  upregulate the release of Th1 cytokines and recruit CD4+CD8+ T cells via CCL5 and
  CXCL10; (C) PARPi promote T-cell infiltration; (D) PARPi increase PD-L1 expression
  by GSK-3β, ATM-ATR-CHK1, and cGAS-STING pathway; (E) PARPi regulate EMT; and (F)
  PARPi inhibit tumor angiogenesis by modulating PARP1/HIF1-α/VEGF signals.ATM indicates
  ataxia telangiectasia-mutated gene; ATR, ataxia telangiectasia and Rad3 related;
  CCL2, C-C motif chemokine ligand 2; CCL5, C-C motif chemokine ligand 5; cGAS, cyclic
  GMP-AMP synthase; CHEK1, checkpoint kinase 1; CXCL10, C-X-C motif chemokine ligand
  10; DAMP, damage-associated molecular pattern; DDR, DNA damage response; EMT, epithelial-mesenchymal
  transition; GSK-3β, glycogen synthase kinase-3β; HIF-1α, hypoxia-inducible factor-1
  α; HR, homologous recombination; ICD, immunogenic cell death; IL, interleukin; INF-g,
  interferon-γ; MHC I, major histocompatibility complex class I; NF-κB, nuclear factor-kB;
  NKG2D(L), natural killer cells group 2D (ligand); PARPi, poly (ADP-ribose) polymerase
  inhibitors; SSB, single-strand breaks; PD-L1, programmed-death ligand 1; STING,
  stimulator of interferon genes; TILs, tumor-infiltrating lymphocytes; VEGF, vascular
  endothelial growth factor; TCR, T cell receptor; mDC, myeloid dendritic cells.
papertitle: The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
reftext: Zhaozhen Wu, et al. Clin Med Insights Oncol. 2021;15:1179554921996288.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.959242
figid_alias: PMC7934064__F2
figtype: Figure
redirect_from: /figures/PMC7934064__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7934064__10.1177_1179554921996288-fig2.html
  '@type': Dataset
  description: The mechanisms involved in DDR and checkpoint immunotherapies. (A)
    PARPi promote antigen presentation by ICD owing to the failure of DNA repair;
    (B) PARPi upregulate the release of Th1 cytokines and recruit CD4+CD8+ T cells
    via CCL5 and CXCL10; (C) PARPi promote T-cell infiltration; (D) PARPi increase
    PD-L1 expression by GSK-3β, ATM-ATR-CHK1, and cGAS-STING pathway; (E) PARPi regulate
    EMT; and (F) PARPi inhibit tumor angiogenesis by modulating PARP1/HIF1-α/VEGF
    signals.ATM indicates ataxia telangiectasia-mutated gene; ATR, ataxia telangiectasia
    and Rad3 related; CCL2, C-C motif chemokine ligand 2; CCL5, C-C motif chemokine
    ligand 5; cGAS, cyclic GMP-AMP synthase; CHEK1, checkpoint kinase 1; CXCL10, C-X-C
    motif chemokine ligand 10; DAMP, damage-associated molecular pattern; DDR, DNA
    damage response; EMT, epithelial-mesenchymal transition; GSK-3β, glycogen synthase
    kinase-3β; HIF-1α, hypoxia-inducible factor-1 α; HR, homologous recombination;
    ICD, immunogenic cell death; IL, interleukin; INF-g, interferon-γ; MHC I, major
    histocompatibility complex class I; NF-κB, nuclear factor-kB; NKG2D(L), natural
    killer cells group 2D (ligand); PARPi, poly (ADP-ribose) polymerase inhibitors;
    SSB, single-strand breaks; PD-L1, programmed-death ligand 1; STING, stimulator
    of interferon genes; TILs, tumor-infiltrating lymphocytes; VEGF, vascular endothelial
    growth factor; TCR, T cell receptor; mDC, myeloid dendritic cells.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Hand1
  - Nelfcd
  - Itk
  - Slc22a3
  - Il2
  - Pdcd1
  - Il6
  - Cxcl15
  - Ccl5
  - Cxcl10
  - Trav6-3
  - Dclk2
  - Cd274
  - Ugt2b5
  - Adam11
  - Ccl22
  - Atr
  - Mmab
  - Sting1
  - Cgas
  - Atm
  - Tpm1
  - Chek1
  - Nfkb1
  - Vegfa
  - Hif1a
  - Parp1
  - Klrk1
  - NELFCD
  - CXCL10
  - CXCL11
  - CXCL12
  - CXCL13
  - CXCL14
  - CXCL9
  - PF4
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - CXCL8
  - PPBP
  - ITK
  - SLC22A3
  - IL2
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - IL6
  - CCL5
  - CD8A
  - CD8B
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - ADGRL2
  - CCDC80
  - DCLK2
  - ERVW-5
  - HLA-C
  - CD274
  - IL12A
  - IL12B
  - ADAM11
  - CCL22
  - ATR
  - ANTXR1
  - MMAB
  - SERPINA2
  - STING1
  - CGAS
  - ATM
  - CHEK1
  - NFKB1
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - HIF1A
  - GNPTAB
  - PARP1
  - KLRK1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - il6
  - cxcl8a
  - ccdc80
  - si:ch211-241b2.5
  - atr
  - cgasa
  - atm
  - chek1
  - vegfaa
  - hif1ab
  - parp1
  - parp14rs2.1
  - TH1
  - PD1
  - TCR
  - tumor
  - HR deficiency
---
